1,2
were not measured. Informed consent for entry of recipients as opposed to Ͻ3 × 10 10 cells/LA procedure with other and donors on to the study was required. mobilizing agents.
3,4 G-CSF also inhibits apoptosis and proBone marrow aspiration from the donor and infusion into longs survival of neutrophils in vitro. [5] [6] [7] [8] In contrast to prethe recipient occurred, by definition, on day 0. During the vious reports using other agents to mobilize LA products, 9 following 5 days, donors received G-CSF for neutrophil sustained and significant increments in the absolute neutromobilization and underwent alternate day collections of phil count (ANC) were observed with infusions of G-CSFprophylactic granulocyte products. On the day of (and submobilized LA products into neutropenic recipients.
1,2,10 sequent to) the bone marrow aspiration, the donor received Neutrophils migrate to sites of inflammation or infection G-CSF 5 g/kg subcutaneously (s.c.) at 12.00 noon and continued daily for 5 consecutive days. LA of the donor began 1 day after the bone marrow harvest (day +1), and of standard procedure 2 on a CS-3000 Plus Blood Cell Sep-CA, USA) introduced into the donor line at a ratio of one part anticoagulant to 10-12 parts blood. Each LA product arator (Baxter, Deerfield, IL, USA). For each collection, 7 l were processed by continuous-flow centrifugation at a was irradiated (25 Gy, 137 Cs Source) prior to infusion into the recipient, to prevent transfusion-associated GVHD. flow rate of approximately 50 ml/min. Clotting was prevented and red blood cell (RBC) sedimentation facilitated Irradiation of neutrophils with 15-40 Gy does not adversely affect neutrophil function.
2 by use of sodium citrate (30 ml of 56.5% trisodium citrate) in 500 ml of 6% HES (McGraw Laboratories, Glendale, Recipients were conditioned with total body irradiation-based regimens. Beginning the day after infusion of alloage such as the terminal ileum and the oral/nasopharynx on the delayed (24 and 48 h post-injection) nuclear scan geneic bone marrow, each recipient received G-CSF 7.5 g/kg intravenously (i.v.) every 12 h until the ANC recoimages was observed and supports the concept that G-CSFmobilized irradiated HLA-matched donor granulocytes are vered to у1500/l for 2 consecutive days. Promptly after completion of each LA collection, the irradiated donor LA able to migrate to sites of inflammation in vivo. Our trial, however, is limited by the relatively small product was transfused i.v. over 1 h into the recipient. Routine pre-medication prior to donor LA product transfusions number of patients, and thus should be confirmed in a larger study. Also, the results we observed in non-alloimmunized, with acetaminophen, diphenhydramine or corticosteroids was not permitted.
HLA-matched recipients of prophylactic granulocyte transfusions should not be generalized to be true for either alloFive recipients underwent indium-labeled donor WBC scans. Briefly, a 2 ml sample of the donor LA product colimmunized patients, HLA-mismatched donor/recipient pairs, or cohorts of recipients with overt infections. In these lected on day +5 was labeled with 500 Ci of indium-111 as previously described, 13 and was subsequently infused i.v. settings, neutrophil migration is adversely affected 19,20 or may be different from our observations. As opposed to the into the recipient. Both anterior and posterior whole body scintigraphic images of the recipient were obtained at 1-4 practice of administration of G-CSF as a single dose before LA collection, our donors received G-CSF daily for 5 conh, 24 and 48 h following injection of indium-labeled donor WBCs. Indium-labeled donor WBC scans were performed secutive days. Progressive immunophenotypic changes in neutrophils with continuing exposure to G-CSF 21-23 may only on day +5 to ensure uniform and essentially total depletion of the recipient's endogenous neutrophil pools as also alter their migration. Thus, the results observed with infusion of indium-labeled neutrophils collected after 5 a result of the transplant regimen, thereby maximizing the opportunity for infused donor neutrophils to localize to sites days of exposure to G-CSF may be different from those with infusion of neutrophils collected after a single G-CSF of inflammation or infection. Only one of the five recipients developed fever or was infected on the day of, and during dose. Finally, neutrophils collected after mobilization with concurrent G-CSF and corticosteroid administration may the 48 h following, infusion of the indium-labeled donor WBCs. This single recipient developed fever on day +5 due also yield different outcomes from this study. to coagulase negative Staphylococcus bacteremia. activity to the spleen and the liver. to sites of inflammation when infused into neutropenic 9 Strauss RG. Therapeutic granulocyte transfusions in 1993.
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human recipients. In the current study, the distribution of determined. Localization of activity to sites of tissue dam-
